{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 56,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 156,
  "notes": "The table uses a heatmap-style color coding where red indicates existing targeted therapy markets and teal indicates blue ocean opportunities.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/5",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.05,
        "y": 0.86
      },
      "kind": "disclaimer",
      "text": "* Post-Osimertinib resistant population shown for EGFRm NSCLC except for SCLC transformation ** Co-occurring activating MAPK pathway alterations exclude EGFR overexpression Source: SEER database (2020), ECIS database (2020), GLOBOCAN database (2020), The AACR Project GENIE Consortium version 8.1 (2020), TCGA Research Network: https://www.cancer.gov/tcga, Tyner JW et al. (2018) PMID: 30333627, Brenner CW et al (2013) PMID: 24120142, Chen J et al. (2020) PMID: 32015526, and Ostrom QT, et al. (2020) PMID: 33123732",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c5d5b2b-78c6-4706-bb9f-282c6d1c01ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.28,
        "x": 0.36,
        "y": 0.835
      },
      "kind": "legend",
      "text": "Blue ocean opportunities (teal) and Red ocean opportunities (red)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd51ac42-1070-41ba-8558-2cc63c6546f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.9,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "table",
      "text": "Table of cancer alterations by type and region",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23d5e092-a504-4cab-9b6f-f3035009be90",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "~5.5m lives at stake annually worldwide with RAS/MAPK pathway alterations; 70+% of unmet needs are “blue oceans” with no approved targeted therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e163f6bf-ae61-489a-a19e-bf07cc4980f1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "20068343-1b91-4fc6-96c1-33b65a540d60",
      "evidence": "~5.5m lives at stake annually worldwide with RAS/MAPK pathway alterations; 70+% of unmet needs are “blue oceans” with no approved targeted therapies",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "Blue Ocean Strategy",
      "slug": null,
      "matchId": "c59e2422-9cc1-4545-b059-9c142411a845",
      "evidence": "Explicit use of 'blue ocean' vs 'red ocean' terminology to categorize market opportunities.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 1,
      "beatId": "38d0ca96-39fe-49b4-b8ae-bc6186fb415b",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Introduction to Erasca and RAS/MAPK pathway",
      "beatSlug": "rags-to-riches-humble-origins",
      "evidence": "Slides 1-5 introduce Erasca's mission, team, and market opportunity",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 5,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "35467dbb-a048-4577-a17f-95d4c07fd9a3",
      "evidence": "Slides 5-10 introduce the pathway and pipeline",
      "position": 0,
      "objective": "Introduce RAS/MAPK pathway and Erasca's pipeline",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}